1. Home
  2. ANL vs SMBK Comparison

ANL vs SMBK Comparison

Compare ANL & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

BUY

Current Price

$10.74

Market Cap

998.8M

Sector

N/A

ML Signal

BUY

Logo SmartFinancial Inc.

SMBK

SmartFinancial Inc.

HOLD

Current Price

$48.95

Market Cap

871.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
SMBK
Founded
2004
N/A
Country
Singapore
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
871.9M
IPO Year
2022
2000

Fundamental Metrics

Financial Performance
Metric
ANL
SMBK
Price
$10.74
$48.95
Analyst Decision
Strong Buy
Buy
Analyst Count
7
6
Target Price
$29.50
★ $52.88
AVG Volume (30 Days)
★ 310.2K
102.3K
Earning Date
08-14-2026
10-19-2026
Dividend Yield
N/A
★ 0.75%
EPS Growth
N/A
★ 39.25
EPS
N/A
★ 1.77
Revenue
N/A
N/A
Revenue This Year
$243.83
$12.42
Revenue Next Year
N/A
$9.45
P/E Ratio
★ N/A
$27.41
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$34.23
52 Week High
$17.25
$54.14

Technical Indicators

Market Signals
Indicator
ANL
SMBK
Relative Strength Index (RSI) 36.09 40.25
Support Level $8.96 $40.28
Resistance Level $12.49 $49.07
Average True Range (ATR) 1.45 1.32
MACD -0.40 -0.13
Stochastic Oscillator 5.63 25.65

Price Performance

Historical Comparison
ANL
SMBK

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About SMBK SmartFinancial Inc.

SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.

Share on Social Networks: